F-Spondin

Drug Profile

F-Spondin

Latest Information Update: 15 Oct 2002

Price : $50

At a glance

  • Originator CeNeS Pharmaceuticals
  • Class Growth factors
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 15 Oct 2002 Discontinued - Preclinical for Spinal cord injuries in USA (unspecified route)
  • 02 Jul 2001 No-Development-Reported for Spinal cord injuries in USA (Unknown route)
  • 16 Feb 2001 Cambridge NeuroScience is now called CeNeS Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top